We demonstrated that ROS play a crucial role in the anti‐thyroid cancer effects of IDET, and our findings revealed that IDET promotes the anti‐thyroid cancer activity of taxol through the modulation of the p62‐Keap1‐Nrf2 pathway with ROS. Here, NFE2L2 is linked to thyroid gland carcinoma.